Edgewise Therapeutics(NASDAQ) EWTX

Edgewise Therapeutics, Inc. makes medicines for serious heart conditions. Its treatments come as pills to help heart muscles work better. The company focuses on helping patients with genetic muscle disorders.

Developing Heart Treatments

• EDG-7500: Selective cardiac sarcomere modulator designed to improve heart muscle contraction; currently in Phase 2 clinical trials for patients with hypertrophic cardiomyopathy.
• EDG-15400: Investigational therapy targeting heart failure with preserved ejection fraction; completed a Phase 1 clinical trial in healthy adults in 2026.
• Discovery Pipeline: Early-stage research efforts focusing on new candidates for various cardiovascular and cardiometabolic conditions.

Moving Beyond Muscular Dystrophy

• Completed the sale of the sevasemten muscular dystrophy program to Servier in July 2026 for $1,550 million in upfront cash.
• Announced positive topline data for the Phase 2 CIRRUS-HCM clinical trial for EDG-7500 in June 2026.
• Planned the initiation of a Phase 3 clinical program for EDG-7500 in the fourth quarter of 2026.
• Advanced the EDG-15400 program with plans to begin a Phase 2 clinical trial in the second half of 2026.

A Precision Discovery Engine

Edgewise utilizes a proprietary precision medicine platform to develop small molecules that modulate specific muscle proteins. The company maintains a lean operational structure with 154 full-time employees and a primary focus on late-stage clinical development for cardiovascular diseases.

Funding the Pipeline

• Net loss was $57.3 million for the three months ended June 30, 2026.
• Research and development expenses reached $47.5 million for the three months ended June 30, 2026.
• Cash and marketable securities totaled $460.7 million as of June 30, 2026, excluding the $1,550 million received from the Sevasemten Sale in July 2026.
• Market capitalization reached $4.8 billion as of the second quarter of 2026.
• Accumulated deficit was $652.7 million as of June 30, 2026, reflecting continuous investment in drug discovery since 2017.

Bottom Line

Edgewise has evolved from a general muscle biology firm into a late-stage cardiovascular specialist. The sale of its muscular dystrophy assets provided a significant capital base to fund its heart disease pipeline through upcoming Phase 3 clinical trials.